DOI QR코드

DOI QR Code

The Preliminary Results of Intensity-Modulated Radiotherapy for Tonsillar Cancer

편도암에 대한 세기조절방사선치료의 예비적 결과

  • Park, Geum-Ju (Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Lee, Sang-Wook (Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Choi, Eun-Kyung (Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Kim, Jong-Hoon (Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Song, Si-Yeol (Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Youn, Sang-Min (Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Park, Sung-Ho (Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Park, Dong-Wook (Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Ahn, Seung-Do (Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine)
  • 박금주 (울산대학교 의과대학 서울아산병원 방사선종양학교실) ;
  • 이상욱 (울산대학교 의과대학 서울아산병원 방사선종양학교실) ;
  • 최은경 (울산대학교 의과대학 서울아산병원 방사선종양학교실) ;
  • 김종훈 (울산대학교 의과대학 서울아산병원 방사선종양학교실) ;
  • 송시열 (울산대학교 의과대학 서울아산병원 방사선종양학교실) ;
  • 윤상민 (울산대학교 의과대학 서울아산병원 방사선종양학교실) ;
  • 박성호 (울산대학교 의과대학 서울아산병원 방사선종양학교실) ;
  • 박동욱 (울산대학교 의과대학 서울아산병원 방사선종양학교실) ;
  • 안승도 (울산대학교 의과대학 서울아산병원 방사선종양학교실)
  • Received : 2009.06.05
  • Accepted : 2009.08.14
  • Published : 2009.09.30

Abstract

Purpose: We wanted to present the preliminary results of intensity-modulated radiotherapy (IMRT) for the treatment of tonsillar cancer. Materials and Methods: We retrospectively analyzed 12 patients who underwent IMRT for tonsillar cancer at Asan Medical Center between November 2002 and February 2007. Seven patients (58%) received definitive treatment, and five (42%) were treated in the postoperative setting. Among the definitively treated patients, 6 patients received cisplatin-based chemotherapy regimens. Simultaneous modulated accelerated radiation therapy (SMART) was used in nine patients. The prescribed dose was 72 Gy at 2.4 Gy/fraction for the definitively treated cases and 61.6 Gy at 2.2 Gy/fraction for the postoperative cases. The median follow-up period was 34 months. Results: All twelve patients completed treatment without interruption, and eleven showed a complete response. One patient had persistent loco-regional disease after treatment. The three-year estimates of loco-regional control, disease-free survival and overall survival were 91.7%, 91.7%, and 100%. The worst acute mucositis was Grade 1 in four patients, Grade 2 in five patients, Grade 3 in two patients and Grade 4 in one patient. Grade 3 xerostomia was observed in six patients. Conclusion: Intensity-modulated radiotherapy was shown to be a safe and effective treatment modality for tonsillar cancer. Further studies with a larger number of patients and a longer follow-up period are needed to evaluate the ultimate tumor control and late toxicity of IMRT for treating tonsillar cancer.

목 적: 편도암 환자를 대상으로 시행한 세기조절방사선치료의 예비적 임상결과를 보고하고자 하였다. 대상 및 방법: 2002년 11월부터 2007년 2월까지 서울아산병원에서 세기조절방사선치료를 시행 받은 12명의 편도암 환자를 대상으로 후향적 분석을 시행하였다. 수술 후 방사선치료는 5명, 근치적방사선치료는 7명에서 시행되었고, 이중 6명의 환자가 cisplatin을 기본으로 하는 항암화학요법과 병용으로 치료를 받았다. 세기조절방사선치료는 9명의 환자에서 동시차등조사가속치료(simultaneous modulated accelerated radiation therapy)가 이용되었다. 근치적치료의 경우 일회선량 2.4 Gy 씩 총 72 Gy, 그리고 수술 후 치료의 경우 일회선량 2.2 Gy 씩 총 61.6 Gy의 방사선량이 조사되도록 하였다. 전체 환자의 추적 관찰 기간은 24~80개월(중앙값 34개월)이었다. 결 과: 전체 대상 환자 12명 모두 치료 중단 없이 계획된 치료를 수행 받았다. 방사선치료 종료 후 11명의 환자에서 완전반응을 보였고 한 명의 환자에서 잔존림프절종양이 발견되어 구제 경부곽청술을 시행하였으나 3개월 후 국소림프절종양이 재발하였다. 완전 반응을 보인 11명의 환자는 마지막 추적 관찰 시점까지 국소림프절 재발 및 원격전이는 관찰되지 않았다. 치료 기간 중 급성 합병증은 Radiation Therapy Oncology Group 3도 이상의 구강 점막염, 인두염과 구강건조증이 각각 3명, 3명, 6명에서 관찰되었다. 결 론: 세기조절방사선치료는 편도암의 치료에 있어서 초기 종양반응과 국소제어면에서 임상적으로 적용 가능한 치료법임을 확인 할 수 있었다. 향후 궁극적인 종양반응과 만성 합병증을 알기 위해서는 추가적인 연구대상과 추적 관찰이 필요하겠다.

Keywords

References

  1. Central Cancer Registry Center. Annual Report of the Central Cancer Registry in Korea, 2002. Seoul; Ministry of Health and Welfare, 2007
  2. Devita VT, Lawrence TS, Steven A, eds. DeVita, Hellman, and Rosenberg’s Cancer: Principles & Practice of Oncology. 8th ed. Philadelpia; Lippincott Williams & Wilkins, 2005:839-844
  3. Bjordal K, Kaasa S, Mastekaasa A. Quality of life in patients treated for head and neck cancer: a follow-up study 7 to 11 years after radiotherapy. Int J Radiat Oncol Biol Phys 1994;28:847-856 https://doi.org/10.1016/0360-3016(94)90104-X
  4. Chao KS, Low DA, Perez CA, Purdy JA. Intensity-modulated radiation therapy in head and neck cancers: the Mallinckrodt experience. Int J Cancer 2000;90:92-103 https://doi.org/10.1002/(SICI)1097-0215(20000420)90:2<92::AID-IJC5>3.0.CO;2-9
  5. Chao KS, Ozyigit G, Tran BN, Cengiz M, Dempsey JF, Low DA. Patterns of failure in patients receiving definitive and postoperative IMRT for head-and-neck cancer. Int J Radiat Oncol Biol Phys 2003;55:312-321 https://doi.org/10.1016/S0360-3016(02)03940-8
  6. Chao KS, Majhail N, Huang CJ, et al. Intensity-modulated radiation therapy reduces late salivary toxicity without compromising tumor control in patients with oropharyngeal carcinoma: a comparison with conventional techniques. Radiother Oncol 2001;61:275-280 https://doi.org/10.1016/S0167-8140(01)00449-2
  7. American Joint Committee on Cancer. AJCC Cancer Staging Manual. 6th ed. New York; Springer, 2002
  8. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995;31:1341-1346 https://doi.org/10.1016/0360-3016(95)00060-C
  9. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481 https://doi.org/10.2307/2281868
  10. Fu KK, Pajak TF, Trotti A, et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000;48:7-16 https://doi.org/10.1016/S0360-3016(00)00663-5
  11. Chao KS, Ozyigit G, Blanco AI, et al. Intensity-modulated radiation therapy for oropharyngeal carcinoma: impact of tumor volume. Int J Radiat Oncol Biol Phys 2004;59:43-50 https://doi.org/10.1016/j.ijrobp.2003.08.004
  12. de Arruda FF, Puri DR, Zhung J, et al. Intensity-modulated radiation therapy for the treatment of oropharyngeal carcinoma: the Memorial Sloan-Kettering Cancer Center experience. Int J Radiat Oncol Biol Phys 2006;64:363-373 https://doi.org/10.1016/j.ijrobp.2005.03.006
  13. Chao KS, Deasy JO, Markman J, et al. A prospectiven study of salivary function sparing in patients with head-andneck cancers receiving intensity-modulated or three-dimensional radiation therapy: initial results. Int J Radiat Oncol Biol Phys 2001;49:907-916 https://doi.org/10.1016/S0360-3016(00)01441-3
  14. Schoenfeld GO, Amdur RJ, Morris CG, et al. Patterns of failure and toxicity after intensity-modulated radiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys 2008;71:377-385 https://doi.org/10.1016/j.ijrobp.2007.10.010
  15. Sanguineti G, Gunn GB, Endres EJ, Chaljub G, Cheruvu P, Parker B. Patterns of locoregional failure after exclusive IMRT for oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2008;72:737-746 https://doi.org/10.1016/j.ijrobp.2008.01.027
  16. Eisbruch A, Marsh LH, Dawson LA, et al. Recurrences near base of skull after IMRT for head-and-neck cancer:implications for target delineation in high neck and for parotid gland sparing. Int J Radiat Oncol Biol Phys 2004;59:28-42 https://doi.org/10.1016/j.ijrobp.2003.10.032
  17. Butler EB, Teh BS, Grant WH 3rd, et al. Smart (simultaneous modulated accelerated radiation therapy) boost:a new accelerated fractionation schedule for the treatment of head and neck cancer with intensity modulated radiotherapy. Int J Radiat Oncol Biol Phys 1999;45:21-32 https://doi.org/10.1016/S0360-3016(99)00101-7
  18. Wu Q, Manning M, Schmidt-Ullrich R, et al. The potential for sparing of parotids and escalation of biologically effective dose with intensity-modulated radiation treatments for head and neck cancers: a treatment design study. Int J Radiat Oncol Biol Phys 2000;46:195-205 https://doi.org/10.1016/S0360-3016(99)00304-1
  19. Wolden SL, Chen WC, Pfister DG, Kraus DH, Berry SL, Zelefsky MJ. Intensity-modulated radiation therapy (IMRT) for nasopharynx cancer: update of the memorial sloan-kettering experience. Int J Radiat Oncol Biol Phys 2006;64:57-62 https://doi.org/10.1016/j.ijrobp.2005.03.057
  20. Chao KS. Dose prescription and target delineation for nodal volume. Philadelphia, PA; Lippincott Co, 2003
  21. Park JH, Lee SW, Back GM, et al. Preliminary results of phase I/II study of simultaneous modulated accelerated (SMART) for nasopharyngeal carcinoma. J Korean Soc Ther Radiol Oncol 2006;24:1-10
  22. Puri DR, Chou W, Lee N. Intensity-modulated radiation therapy in head and neck cancers: dosimetric advantages and update of clinical results. Am J Clin Oncol 2005;28:415-423 https://doi.org/10.1097/01.coc.0000162443.08446.00